Bottneuro AG | Leading provider of diagnosis and treatment of AD

Who We Are

Founded in 2021, Bottneuro AG is a pioneering medtech startup dedicated to transforming the treatment of neurological diseases. Our mission is driven by a passionate team, supported by highly experienced advisors and entrepreneurs who bring extensive expertise to every aspect of our work.

As a spin-off from the University of Basel, Bottneuro has validated the therapeutic potential of alternating microcurrents on glial cells—a breakthrough made possible with financial backing from the Gebert Rüf Stiftung. In our first year, we achieved notable milestones, including winning all three stages of the prestigious Venture Kick Program and being recognized by Forbes Magazine as a spin-off to watch in the DACH region, positioning us at the forefront of non-invasive Alzheimer’s treatment.

Solution

Why join the Bottneuro team?

Make the world
a better place

We are dedicated to providing innovative solutions that can help patients with neurological diseases regain their independence and improve their quality of life.

Join a caring
and like-minded team

We are a diverse team with different backgrounds, cultures, and nationalities. The interactive working environment at the Novartis Campus invites great people to connect.

Unleash your
creative potential

We believe that creativity is the key to success, and we value the contributions of every member of our team. We are always looking for exceptional talents.


Open Positions

Upcoming job opportunities will be available soon!
You are welcome to check back on the page at a later time.

Our Team

Inspiration comes of working every day - but only with a positive mindset. I want to ‎ensure that technology simplifies the everyday life of all those who are particularly ‎challenged by health issues.

Dr. Bekim Osmani
Dr. Bekim Osmani
CEO and Co-Founder

I am ‎convinced that by expanding our knowledge about neurodegenerative diseases we ‎are able to limit and counteract harmful disease progression.

Dr. Alois C. Hopf
Dr. Alois C. Hopf
CSO and Co-Founder

At Bottneuro, I have taken on the challenge of digital therapy for neurodegenerative diseases, helping to expand the technology and push it towards personalised treatment.

Mahyar Joodaki
Mahyar Joodaki
Head of Digital Therapeutics

I am fascinated about psychology and neuroscience to better understand human behavior.

Annina Ruffner
Annina Ruffner
Client Service Manager

I studied business and economics at University in Basel before turning to medical informatics at FHNW in Muttenz/Olten.

Marc Funken
Marc Funken
Quality and Compliance Manager
Mathias Recalde Koller
Design Engineer

I'm inspired to help treat neurodegenerative diseases at Bottneuro.

Dr. Griffin Rodgers
Dr. Griffin Rodgers
Computational Scientist
Prof. Dr. Raphael Guzman
Prof. Dr. Raphael Guzman
Co-Founder and Clinical Advisor
Prof. Dr. phil. Andreas Monsch
Prof. Dr. phil. Andreas Monsch
Clinical Advisor
Prof. Dr. Emiliano Santarnecchi
Prof. Dr. Emiliano Santarnecchi
Scientific Advisor
Dr. Antonella Santuccione Chadha
Dr. Antonella Santuccione Chadha
Clinical Advisor
Prof. Christoph Michel
Prof. Christoph Michel
Scientific Advisor
Lucie Bréchet
Lucie Bréchet
Scientific Advisor
Patrick Griss
Patrick Griss
Advisor to the Board
Sophie Lamparter
Sophie Lamparter
Advisor US Market
Guido Mesmer
Guido Mesmer
Financial and M&A Advisor
David Eiler
David Eiler
Regulatory and QMS
Dr. Bekim Osmani
Dr. Bekim Osmani
CEO and Co-Founder
Rolf Wildermuth
Rolf Wildermuth
Chairman of the Board, Former CEO Medtronic CH
Pascal Brenneisen
Pascal Brenneisen
Board Member, Former CEO Novartis CH
Dr. Tino Töpper
Dr. Tino Töpper
Board Member, Advisor
We use cookies to personalize content and to analyze our traffic. Please decide if you are willing to accept cookies from our website.